Patents Assigned to Allergan, Inc.
  • Patent number: 11648104
    Abstract: A breast implant includes a flexible shell having an anterior face including an outer surface and an inner surface, and a marker attached to the inner surface of the anterior face of the shell. The marker includes a first layer of material having a radiopaque surface with readable characters for identifying a characteristic of the breast implant while in vivo, and a second layer of non-radiopaque material laminated onto the radiopaque surface. The readable characters defined by an outline formed from an absence of at least a portion of material of the radiopaque surface. The first layer of material with the readable characters is interposed between the inner surface of the anterior face of the shell and the second layer, and the readable characters are viewable in vivo using conventional imaging techniques.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: May 16, 2023
    Assignee: Allergan, Inc.
    Inventors: David J. Schuessler, Alberto Flores-Pujol, Daniela Rodriguez-Estrada
  • Patent number: 11530400
    Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.
    Type: Grant
    Filed: June 8, 2022
    Date of Patent: December 20, 2022
    Assignee: Allergan, Inc.
    Inventors: Jennifer L. Ton, Hemant A. Patel, Ronald C. Bates, Wajdie M. Ahmad
  • Patent number: 11524075
    Abstract: Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: December 13, 2022
    Assignee: Allergan, Inc.
    Inventor: Terrence J. Hunt
  • Patent number: 11525130
    Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.
    Type: Grant
    Filed: January 19, 2022
    Date of Patent: December 13, 2022
    Assignee: Allergan, Inc.
    Inventors: Jennifer L. Ton, Hemant A. Patel, Ronald C. Bates, Wajdie M. Ahmad
  • Patent number: 11518986
    Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.
    Type: Grant
    Filed: March 15, 2022
    Date of Patent: December 6, 2022
    Assignee: Allergan, Inc.
    Inventors: Jennifer L. Ton, Hemant A. Patel, Ronald C. Bates, Wajdie M. Ahmad
  • Patent number: 11497598
    Abstract: A breast implant is provided which includes a filling, or core having a lower overall density relative to silicone gel-filled or saline-filled implant. The core may be a composite including flexible bodies, for example, air-containing or gas-containing bodies, and a gel medium between or around the bodies.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: November 15, 2022
    Assignee: Allergan, Inc.
    Inventor: David Schuessler
  • Patent number: 11446382
    Abstract: Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: September 20, 2022
    Assignee: Allergan, Inc.
    Inventor: Terrence J. Hunt
  • Patent number: 11331306
    Abstract: The present invention relates to pharmaceutical compositions, containing 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, (S) 4-[1-(2,3-dimethylphenylpethyl]-1H-imidazole or (S) [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, their use as pharmaceuticals for the treatment of retinal diseases, for retinal neuroprotection and vision enhancement.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: May 17, 2022
    Assignee: ALLERGAN, INC.
    Inventors: Mohammed I. Dibas, John E. Donello, Daniel W. Gil
  • Patent number: 11332518
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: May 17, 2022
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton E. Garay, Lina Wong, D. Dianne Hodges, Kei Roger Aoki
  • Patent number: 11326155
    Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.
    Type: Grant
    Filed: October 19, 2021
    Date of Patent: May 10, 2022
    Assignee: Allergan, Inc.
    Inventors: Jennifer L. Ton, Hemant A. Patel, Ronald C. Bates, Wajdie M. Ahmad
  • Patent number: 11286234
    Abstract: The present invention relates to phenyl urea derivatives useful for the treatment of inflammatory diseases, pharmaceutical compositions containing them and their use as tools or as pharmaceuticals as modulators of the N-formyl peptide receptor (FPR), including FPR1 and FPR2, or as selective agonists of the FPR1 receptor.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: March 29, 2022
    Assignee: Allergan, Inc.
    Inventors: Tien T. Duong, Richard L. Beard, Michael E. Garst
  • Patent number: 11285134
    Abstract: Described herein are methods and compositions for the treatment of ocular conditions and for the improvement of vision parameters using pharmaceutically acceptable ophthalmic pilocarpine formulations. A nonlimiting example of an ocular condition that may be treated with the methods and compositions disclosed herein is presbyopia.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: March 29, 2022
    Assignee: ALLERGAN, INC.
    Inventors: Michael R. Robinson, Mohammed Dibas, Jaya Giyanani, Anuradha Gore, Sungwook Lee, Haixia Liu, Aileen Morgan, Jihao Zhou
  • Patent number: 11285216
    Abstract: Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: March 29, 2022
    Assignee: Allergan, Inc.
    Inventor: Terrence J. Hunt
  • Patent number: 11261240
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: March 1, 2022
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton E. Garay, Lina Wong, D. Diane Hodges, Kei Roger Aoki
  • Patent number: 11248219
    Abstract: Single chain polypeptide fusion protein, comprising: a non-cytotoxic protease capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a galanin targeting moiety; a protease cleavage site; a translocation domain; a first spacer located between the non-cytotoxic protease and the protease cleavage site; and a second spacer located between the galanin targeting moiety and the translocation domain.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: February 15, 2022
    Assignees: Ipsen Bioinnovation Limited, Allergan, Inc.
    Inventors: Peter James, Keith Foster, John Chaddock, Roger Aoki, Lance Steward, Joseph Francis
  • Patent number: 11208377
    Abstract: Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula: The compounds are useful for treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: December 28, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Christopher D. Hein, Tien T. Duong, Santosh Sinha, Ling Li, Jeremiah H. Nguyen, David W. Old, Robert Burk, Veena Viswanath, Sandhya Rao, John E. Donello
  • Patent number: 11203748
    Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.
    Type: Grant
    Filed: June 7, 2021
    Date of Patent: December 21, 2021
    Assignee: Allergan, Inc.
    Inventors: Jennifer L. Ton, Hemant A. Patel, Ronald C. Bates, Wajdie M. Ahmad
  • Patent number: 11202853
    Abstract: The present specification discloses porogen compositions comprising a core material and shell material, methods of making such porogen compositions, methods of forming such porous materials using such porogen compositions, biocompatible implantable devices comprising such porous materials, and methods of making such biocompatible implantable devices.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: December 21, 2021
    Assignee: Allergan, Inc.
    Inventors: Futian Liu, Nicholas J Manesis, Xiaojie Yu, Athene W. Chan
  • Patent number: 11185641
    Abstract: Skin can be treated by piercing skin with a plurality of needles of an injection device and ejecting a dose of fluid therethrough. The device can include a housing, a plunger disposed in the housing, a cartridge disposed in the housing, and one or more dosing chambers. The plurality of needles can be coupled to the housing and be in fluid communication with the cartridge. Advancement of the plunger can cause a dose of fluid to be ejected from the plurality of needles.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: November 30, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Ethan Franklin, Dimitrios Stroumpoulis, Zachary Dominguez, Justin Schwab, Bastien Mandaroux, Edwin Kayda
  • Patent number: D977647
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: February 7, 2023
    Assignee: Allergan, Inc.
    Inventors: David J. Schuessler, Alberto J. Flores, Daniela Rodriguez, Luis M. Solano